9-11 January 2023, San Francisco
Edison is pleased to announce that we will be resuming in-person meetings for San Francisco Healthcare week 2023.
We represent several companies in the healthcare space including medtechs, biotechs, diagnostics, and specialists in emerging diseases.
Below is our list of clients attending, to schedule a 1×1 please fill out our form here and someone from the Edison team will reach out for scheduling.
If you have any other questions, feel free to contact us.
See you there.
Antisense Therapeutics is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and reported highly promising Phase II trial results.
Biomica is a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics utilising a dedicated Computational Predictive Biology platform, licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings.
Context Therapeutics is a clinical-stage biopharmaceutical company committed to advancing medicines for female cancers. The company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer-signalling pathways.
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) or bioimpedance technology and Artificial Intelligence (AI).
Medlab Clinical is pioneering the development and commercialization of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab’s pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.
MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders. Their mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. MindMed is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
OpGen is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies.
SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. SIGA’s lead product is TPOXX®, also known as tecovirimat, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease (FDA approved) and other orthopoxviruses such as monkeypox (currently in clinical trials for FDA approval).
VolitionRx is a multinational epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
Contact form has failed to render due to missing field values:
Should investors buy REITs that have exposure to the office sector?
Get access to the very latest content matched to your personal investment style.